Insmed price target raised to $177 from $175 at Wells Fargo

Wells Fargo raised the firm’s price target on Insmed (INSM) to $177 from $175 and keeps an Overweight rating on the shares. The firm thinks the Arikayce top line data look good, albeit it would like to learn more about the robustness of the RSS primary endpoint. Wells is raising its Arikayce first line probability of success to 80% from 50%.